Cargando…

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients

Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	ROŽMAN, SAMO, NOVAKOVIĆ, SRDJAN, GRABNAR, IZTOK, CERKOVNIK, PETRA, NOVAKOVIĆ, BARBARA JEZERŠEK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/ https://www.ncbi.nlm.nih.gov/pubmed/27123112 http://dx.doi.org/10.3892/ol.2016.4402

Ejemplares similares

FcγRIIa and FcγRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
por: Mimoto, F., et al.
Publicado: (2013)

Significant differences in FcγRIIa, FcγRIIIa and FcγRIIIb genes polymorphism and anti-malarial IgG subclass pattern are associated with severe Plasmodium falciparum malaria in Saudi children
por: Nasr, Amre, et al.
Publicado: (2021)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
por: Anania, Jessica C., et al.
Publicado: (2018)

Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors
por: Isoda, Yuya, et al.
Publicado: (2015)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2015)

Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
por: Maemura, Tadashi, et al.
Publicado: (2021)

Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant
por: Phaahla, Ntando G., et al.
Publicado: (2019)

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2016)

Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC
por: Mao, Changchuin, et al.
Publicado: (2021)

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index
por: Karimifar, Mansoor, et al.
Publicado: (2021)

Analysis of HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcγRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility
por: Jönsen, Andreas, et al.
Publicado: (2004)

Role of N-Glycosylation in FcγRIIIa interaction with IgG
por: Van Coillie, Julie, et al.
Publicado: (2022)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa(V158) Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
por: Kang, Tae Hyun, et al.
Publicado: (2019)

The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation
por: Shibata-Koyama, Mami, et al.
Publicado: (2009)

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index
por: Karimifar, Mansoor, et al.
Publicado: (2022)

FcγRIIa defunctioning polymorphism in paediatric patients with renal allograft
por: Fadel, Fatina I., et al.
Publicado: (2017)

A tail of two ITAMs: GPVI/FcRγ and FcγRIIa's role in platelet activation and thrombus stability
por: Neeves, Keith B.
Publicado: (2021)

The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease
por: Chang, Ling-Sai, et al.
Publicado: (2016)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience
por: Kokovic, Ira, et al.
Publicado: (2014)

Biophysical Characterization of the Contribution of the Fab Region to the IgG-FcγRIIIa Interaction
por: Kosuge, Hirofumi, et al.
Publicado: (2022)

Neutrophil FcγRIIA availability is associated with disease activity in systemic lupus erythematosus
por: Bengtsson, Anders A., et al.
Publicado: (2020)

Endothelial Shear Stress and Platelet FcγRIIa Expression in Intracranial Atherosclerotic Disease
por: Liebeskind, David S., et al.
Publicado: (2021)

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
por: Bohländer, Fabian, et al.
Publicado: (2021)

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
por: Cox, Freek, et al.
Publicado: (2016)

Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa
por: Miao, Shuo, et al.
Publicado: (2019)

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation
por: Rijkers, Maaike, et al.
Publicado: (2018)

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling
por: Okubo, Koshu, et al.
Publicado: (2021)

Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase
por: Duan, Rundan, et al.
Publicado: (2021)

FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation
por: Riechert, Vanessa, et al.
Publicado: (2023)

Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa
por: Kannicht, Christoph, et al.
Publicado: (2020)

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production
por: Capuano, Cristina, et al.
Publicado: (2017)

The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study
por: Büyükkurt, Nurhilal, et al.
Publicado: (2015)

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV
por: Talathi, Sneha Pramod, et al.
Publicado: (2019)

Oligomannose N-Glycans 3D Architecture and Its Response to the FcγRIIIa Structural Landscape
por: Fogarty, Carl A, et al.
Publicado: (2021)

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression
por: Bournazos, Stylianos, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_r5epmue2dji8u13q5objfn4jvs